Changes in research to overcome the problem of resistance to new CLL drugs
What influence do circulating myeloma plasma cells have on the treatment of multiple myeloma?
Safety analysis of the BCL-2 inhibitor venetoclax for CLL
Treatment for older AML patients - when is an allogeneic transplant suitable?
New aims and next steps for adult ALL induction therapy